J Exp Med 217:20201129
Disclosures: Vaclav Smid: Nothing to Disclose, Ksenyia Dryahina: Nothing to Disclose, Barbora Novkov: Nothing to Disclose, Stefan Swift: Nothing to Disclose, Simon Dostal: Nothing to Disclose, Sarka Svobodova: Nothing to Disclose, Martin Lenicek: Nothing to Disclose, Patrik Spanel: Nothing to Disclose, Radan Bruha: Nothing to Disclose 855 BASELINE CHARACTERISTICS IN WELL-COMPENSATED NASH CIRRHOSIS PATIENTS DIAGNOSED WITH OR WITHOUT A LIVER BIOPSY IN MAESTRO-NASH-OUTCOMES, A CLINICAL OUTCOME PHASE 3 STUDY ASSESSING THE EFFECT OF RESMETIROM IN WELL COMPENSATED NASH CIRRHOSIS Meena Bansal 1 Jrn Schattenberg 2 Kris Kowdley 3 Mazen Noureddin 4 Rohit Loomba 5 Rebecca Taub 6 Dominic Labriola 6 David Schneider 6 , 1 Icahn School of Medicine at Mount Sinai (ISMMS), 2 Saarland University Medical Center, Homburg and Saarland University, 3 Liver Institute Northwest, 4 Houston Methodist Hospital, 5 University of California, San Diego, 6 Madrigal Pharmaceuticals Background: MAESTRO- NASH Outcomes (NCT05500222) is a multi-national, multicenter, double-blind, randomized, placebo-controlled study in well-compensated NASH cirrhosis
On top of that, Nootropics Depot satisfies the safety criteria we prefer a berberine producer to meet: GMP compliance and third-party testing
Wellness injections , such as glutathione, may provide an opportunity to explore benefits related to oxidative stress support and overall vitality
